LadRx Corp financial data

Symbol
LADX on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
11726 San Vicente Boulevard, Suite 650, Los Angeles, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CYTRX CORP (to 9/23/2022)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 135 % +16.4%
Return On Equity -317 % -150%
Return On Assets -87.7 % +34.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 495 K shares -98.9%
Common Stock, Shares, Outstanding 495 K shares -98.9%
Entity Public Float 1.1 M USD -72.5%
Common Stock, Value, Issued 495 USD -98.9%
Weighted Average Number of Shares Outstanding, Basic 495 K shares +7.44%
Weighted Average Number of Shares Outstanding, Diluted 495 K shares +7.44%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 30.3 K USD
General and Administrative Expense 3.25 M USD -24.9%
Operating Income (Loss) -3.58 M USD +17.7%
Nonoperating Income (Expense) 1.42 K USD
Net Income (Loss) Attributable to Parent -2.54 M USD +36.2%
Earnings Per Share, Basic 1.09 USD/shares
Earnings Per Share, Diluted 1.09 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.06 M USD +240%
Cash, Cash Equivalents, and Short-term Investments 4.1 M USD -51.2%
Assets, Current 2.22 M USD +114%
Property, Plant and Equipment, Net 4.65 K USD -70.2%
Operating Lease, Right-of-Use Asset 31.6 K USD -85.4%
Other Assets, Noncurrent 1.48 K USD -80.9%
Assets 2.22 M USD +80.5%
Accounts Payable, Current 892 K USD -20.8%
Employee-related Liabilities, Current 157 K USD -22.7%
Liabilities, Current 1.88 M USD -20.1%
Operating Lease, Liability, Noncurrent 33.5 K USD -84.5%
Liabilities 2.2 M USD -0.92%
Retained Earnings (Accumulated Deficit) -488 M USD +0.34%
Stockholders' Equity Attributable to Parent 345 K USD
Liabilities and Equity 2.22 M USD +80.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -700 K USD +52.9%
Net Cash Provided by (Used in) Financing Activities -68.8 K USD +66.6%
Common Stock, Shares Authorized 62.4 M shares 0%
Common Stock, Shares, Issued 495 K shares -98.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.88 K USD +99.2%
Deferred Tax Assets, Valuation Allowance 105 M USD -6.05%
Deferred Tax Assets, Gross 105 M USD -6.05%
Operating Lease, Liability 33.6 K USD -85.4%
Payments to Acquire Property, Plant, and Equipment 766 USD
Lessee, Operating Lease, Liability, to be Paid 33.7 K USD -85.6%
Property, Plant and Equipment, Gross 48.7 K USD 0%
Operating Lease, Liability, Current 33.6 K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 33.7 K USD -83.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 33.7 K USD -83.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 67 USD -98.7%
Deferred Tax Assets, Operating Loss Carryforwards 74.8 M USD -0.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 833 K shares 0%
Additional Paid in Capital 489 M USD +0.11%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.06 K USD -30.4%
Share-based Payment Arrangement, Expense 51.1 K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%